Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation.
|
| Abstract |
We describe a 35-year-old woman with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who received allogeneic sibling donor peripheral blood stem cell transplantation (PBSCT) and entered a second complete remission. Upon detection of BCR-ABL transcripts after PBSCT, the patient received imatinib, leading to molecular remission. Following the failure of donor leukocyte infusions, she underwent reduced-intensity unrelated cord blood transplantation (RI-UCBT), and has continued durable molecular remission for more than 30 months without substantial graft-versus-host disease. Because of a lack of adverse effects of imatinib on transplantation outcome, a treatment strategy consisting of molecular monitoring-guided initiation of imatinib followed by RI-UCBT may be promising in the management of Ph+ ALL after allogeneic SCT.
|
|---|---|
| Authors | Akiyoshi Takami, Shigeru Shimadoi, Chiharu Sugimori, Kenichi Takemoto, Masami Shibayama, Tomotaka Yoshida, Tohru Murayama, Kenichi Nagai, Koichi Miyamura, Hidesaku Asakura, Shinji Nakao |
| Journal | International journal of hematology (Int J Hematol) Vol. 84 Issue 2 Pg. 170-3 (Aug 2006) ISSN: 0925-5710 [Print] Japan |
| PMID | 16926141 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!